anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An animal anesthetization device facilitates anesthetization of an animal, or simultaneous anesthetization of a litter of animals, prior to a procedure such as tail docking, castration, or the like. The device includes a box having a bottom wall and a perimeter wall coupled to and extending upwardly from the bottom wall defining an interior space. A lid is coupled to the box wherein the interior space is selectively enclosed. A valve is coupled to the box. A canister has a dispensing nozzle which is selectively engageable to the valve wherein contents of the canister are dispensed into the interior space of the box. An anesthetizing agent is positioned in the canister and dispensed into the box to anesthetize one or more animals in the box.
Risk Summary

Breastfeeding is not expected to result in clinically relevant exposure of the infant to desmopressin following maternal administration. Desmopressin is poorly transferred into human breastmilk at negligible amounts (see Data) . There is no information on the effects of desmopressin on the breastfed child or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for desmopressin acetate injection and any potential adverse effects on the breastfed child from desmopressin acetate injection or from the underlying maternal condition. 

Data

The breast milk of lactating women was collected over 8 hours following administration of 300 mcg desmopressin nasal spray. The expected area under the plasma concentration time curve (AUC) of desmopressin following 300 mcg nasal spray is 2.4-fold higher to that of 4 mcg desmopressin acetate injection. Based on the measured concentrations of desmopressin following intranasal administration, the amounts of desmopressin that may be transferred to a breastfed infant correspond to 0.0001 to 0.005% of the dose administered.
This study was led by the Fujian Provincial Maternal and Child Health Hospital, with the following research centers: Xiangya Hospital of Central South University, Fujian Provincial Center for Disease Control and Prevention, Shenzhen Maternal and Child Health Hospital, Hubei Provincial Maternal and Child Health Hospital, Shandong Province and Shaanxi Province. Recruitment was conducted in 6 provinces in different regions of China, and 2000 subjects were recruited in each province. A total of 12,000 subjects were recruited. Each subject was evaluated within 3 to 12 months after the last dose of HPV vaccine, and adverse reaction symptoms were queried by telephone follow-up and face-to-face. Peripheral blood 1 tube (3ml) was collected to detect the concentration of comprehensive antibodies to HPV vaccine. A multicenter cohort study was conducted to evaluate the effectiveness of HPV vaccine and to monitor the symptoms of adverse reactions to HPV vaccine in the female population of appropriate age.
Transgenic plants expressing cobalamin (vitamin B12) binding proteins are claimed. Constructs, vectors and transformed cells are also claimed. The binding protein may be any one of transcobalamin, intrinsic factor, haptocorrin, methylmalonyl-CoA mutase or methionine synthase. Also claimed are methods of isolating the expressed protein, pharmaceutical compositions and foodstuffs containing the expressed protein. The use of the protein in diagnostic tests, such as a Schilling test for identifying cobalamin absorption in the gut is claimed. Methods of treating cobalamin deficiency by administering the protein are disclosed and claimed.
PURPOSE:To simplify various production processes and obtain a solid powdery cosmetic, by using a fluorohydrocarbon as a blending solvent, blending the fluorohydrocarbon with a powdery cosmetic base while stirring, forming the resultant blend into a granular material, etc., filling the blend in a cosmetic container and volatilizing the fluorohydrocarbon after filling. CONSTITUTION:A powder cosmetic base containing much pearling agent powder, e.g. titanium-mica based agent, etc., is blended with a fluorohydrocarbon, e.g. Flon-Showa FS-11(R), etc., having <=50 deg.C boiling point while stirring by a suitable method to give a granular or liquid form. The resultant material is then filled in a cosmetic container and the fluorohydrocarbon is volatilized after filling. The powder is readily pressurized while applying a screen, e.g. cloth or paper, to the powder surface to afford the aimed solid powdery cosmetic. EFFECT:The fluorohydrocarbon has good affinity for the cosmetic base and stirring and blending are facilitated. Since equipment required for the stirring may be simple and the fluorohydrocarbon is readily volatilized, the pressurizing operation after the volatilization may be simple.
The invention relates to enteromorpha bedsore powder. The powder is prepared by the following steps: mixing the following main components according to a proportion: enteromorpha, chitin, coptis chinensis, radix tinosporae and semen plantaginis, drying and grinding to prepare the compound enteromorpha bedsore powder. Bedsore is also called pressure ulcer, is a frequently-occurring disease and a common disease of aged people, and is mainly caused by that a local part of a body surface is pressed due to long-time bed-ridden, which causes disordered nerves and nutrition, unsmooth blood pressure circulation, continuous ischemia of soft tissues and skin resistance reduction. Various types of existing bedsore powder are different in performance, are sorted into high, medium and low efficacies, are toxic, and do not have excellent biological safety. The enteromorpha bedsore powder has the characteristics of diminishing inflammation, relieving pain, inhibiting bacteria, disinfecting, and stimulating skin, cornea and conjunctiva and muscles, is nontoxic to keratinocyte and fibroblast, and has good healing repairing performance and biological safety. The enteromorpha bedsore powder can be used for diminishing inflammation, relieving pain, inhibiting bacteria, disinfecting, refreshing, preventing adhesion and promoting skin tissue healing and repairing for various types of bedsores.
The invention discloses helicobacter pylori adhesion-related protein MHC-II restriction antigen epitope peptide and application thereof, and relates to the field of biological medicine. The amino acid sequence of the helicobacter pylori adhesion-related protein MHC-II restricted antigen epitope peptide disclosed by the invention is shown in SEQ ID NO. 1-20. The multi-epitope peptide ADHESIVE MHC-II PEPTIDE is formed by connecting MHC-II restriction antigen epitope peptide screened by adhesion related protein HpaA, alpA, alpB, babA and SabA with the amino acid sequence of mycobacterium tuberculosis Rv0652 50S ribosomal protein L7/L12 in series, and the amino acid sequence is shown as SEQ ID NO. 22. Expressing the multi-epitope peptide ADHESIVE MHC-II PEPTIDE by using escherichia coli, and obtaining the ADHESIVE MHC-II PEPTIDE multi-epitope vaccine through protein purification.
The proposed research design will be utilizing a randomized cross over repeated measures design. Subjects will take part in two separate conditions: 1) One hour of a beginning martial art class (EP), and 2) One hour walk at 4.0 mph pace (IP).
BACKGROUND/AIM: Bloodstream infections in patients with COVID-19 are linked to higher mortality rates, whilst data on epidemiology and resistance patterns remains scarce to guide management and prevent antibiotic resistance. This research focuses on the prevalence, clinical features, causative microorganisms, and antimicrobial susceptibility of bacterial and fungal secondary bloodstream co-infections in hospitalized patients with COVID-19.
PATIENTS AND METHODS: In this retrospective study analysis of 230 patients with COVID-19 from Central Taiwan (June 2021 to June 2022), pathogens were identified via MALDI-TOF MS and Vitek 2 system with Clinical & Laboratory Standards Institute (CLSI) standards.
RESULTS: In the cohort, 17.8% experienced bloodstream infections, resulting in a total of 45 isolates from the 41 bloodstream infection patients: predominantly gram-positive bacteria (Staphylococcus and Enterococcus) at 69%, gram-negative at 29% (Escherichia coli and Klebsiella pneumoniae), and fungi at 2%. Infected patients showed significantly elevated levels of white blood count (WBC), C-reactive protein (CRP) and procalcitonin (PCT). Of note, resistance to common antibiotics, such as fluoroquinolones, cephalosporins, and oxacillin was significant, especially in K. pneumoniae, Acinetobacter species, and S. aureus infections.
CONCLUSION: Our study highlights the influence of bacterial infections in hospitalized patients with COVID-19. The bacterial infections were discovered to impact the clinical trajectory of COVID-19, potentially exacerbating or mitigating its symptoms, severity and fatality. These insights are pivotal to addressing clinical challenges in COVID-19 management and underscoring the need for tailored medical interventions. Understanding these co-infections is thus essential for optimizing patient care and improving overall outcomes in the post COVID-19 pandemic era.
The invention belongs to the field of traditional Chinese medicines, relates to a new use of a rhizoma gastrodiae pill prescription in pharmacy, and concretely relates to an application of the rhizoma gastrodiae pill prescription in preparation of anti-ageing medicines. Ageing is a natural process of life, and is mainly characterized in that body functions, stability and stress ability of internal environment and structures and functions of body cells, tissues and organs decrease with age. A method for fundamentally improving the survival quality of premature senility colonies is to find medicines for improving body functions and delaying ageing in order to make the colonies age healthily. The invention provides the application of the rhizoma gastrodiae pill prescription in preparation of anti-ageing medicines. Animal experiments show that the rhizoma gastrodiae pill prescription can substantially prolong the life of the premature senility colonies. The invention provides the new use of the rhizoma gastrodiae pill prescription. The rhizoma gastrodiae pill prescription can be applied in the preparation of the anti-ageing medicines, so the rhizoma gastrodiae pill prescription is expected to be exploited into new generation of anti-ageing medicines.
The CVT will be based on Meerschman et al. (2019). This therapeutic program has been proven effective in voice therapy and is the standard clinical care for FD patients. The program is a combination of education, vocal hygiene, posture, local relaxation, costo-abdominal breathing, resonant voice, voice placing, forward focus, voice onset, semi-occluded vocal tract exercises and laryngeal manipulation. Identical to the ANS regulation therapy, participants will practice 20 min a day for 1 month. One weekly session will be organized in the clinic under the guidance of the therapist (individual sessions), the other sessions will be organized at home and tracked by the RedCap app.
Treatment sequence consists of eight chemotherapy courses and two blinatumomab courses. Patients not in CR after chemotherapy course 2 will go off-study.
BACKGROUND: This umbrella review aimed to summarize the findings and conclusions of published systematic reviews on the prophylactic role of mesh against parastomal hernias in colorectal surgery.
METHODS: PRISMA-compliant umbrella overview of systematic reviews on the role of mesh in prevention of parastomal hernias was conducted. PubMed and Scopus were searched through November 2023. Main outcomes were efficacy and safety of mesh. Efficacy was assessed by the rates of clinically and radiologically detected hernias and the need for surgical repair, while safety was assessed by the rates of overall complications.
RESULTS: 19 systematic reviews were assessed; 7 included only patients with end colostomy and 12 included patients with either ileostomy or colostomy. The use of mesh significantly reduced the risk of clinically detected parastomal hernias in all reviews except one. Seven reviews reported a significantly lower risk of radiologically detected parastomal hernias with the use of mesh. The pooled hazards ratio of clinically detected and radiologically detected parastomal hernias was 0.33 (95%CI: 0.26-0.41) and 0.55 (95%CI: 0.45-0.68), respectively. Six reviews reported a significant reduction in the need for surgical repair when a mesh was used whereas six reviews found a similar need for hernia repair. The pooled hazards ratio for surgical hernia repair was 0.46 (95%CI: 0.35-0.62). Eight reviews reported similar complications in the two groups. The pooled hazard ratio of complications was 0.81 (95%CI: 0.66-1).
CONCLUSIONS: The use of surgical mesh is likely effective and safe in the prevention of parastomal hernias without an increased risk of overall complications.
Optional third mRNA-1273 vaccination sub-study. 100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle after Day 209 in participants from Arm 1,4,7,10, 11, and 12 from 18 years of age or older. N=70.
PURPOSE: A composition for treating and diagnosing diseases caused by ErbB2 signal or expression is provided to use as a tumor imaging device and anti-tumor composition. CONSTITUTION: An anti-ErbB2 RNA aptamer is denoted by general formula 1 (X1-GAR1GGGAGN1GR2N2AGGR3UAGN3N4N5-X2). In general formula 1, R1-R3 are A or G, N1-n5 are all nucleotides; X1 does not exist or is at least one nucleotide; and X2 does not exist or at least one nucleotide. The anti-ErbB2 RNA aptamer has a nucleotide selected from sequence numbers 1-4. A material controlling ErbB2 activation contains RNA aptamer. A composition for diagnosing or treating ErbB2 contains the material. A composition for detecting tumor contains RNA aptamer.
BACKGROUND: Chronic inflammation contributes to the progression of isoproterenol (ISO)-induced heart failure (HF). Caspase-associated recruitment domain (CARD) families are crucial proteins for initiation of inflammation in innate immunity. Nonetheless, the relevance of CARDs in ISO-driven cardiac remodelling is little explored.
METHODS: This study utilized Card9-/- mice and reconstituted C57BL/6 mice with either Card9-/- or Otud1-/- marrow-derived cells. Mechanistic studies were conducted in primary macrophages, cardiomyocytes, fibroblasts and HEK-293T cells.
RESULTS: Here, we demonstrated that CARD9 was substantially upregulated in murine hearts infused with ISO. Either whole-body CARD9 knockout or myeloid-specific CARD9 deletion inhibited ISO-driven murine cardiac inflammation, remodelling and dysfunction. CARD9 deficiency in macrophages prevented ISO-induced inflammation and alleviated remodelling changes in cardiomyocytes and fibroblasts. Mechanistically, we found that ISO enhances the activity of CARD9 by upregulating ovarian tumour deubiquitinase 1 (OTUD1) in macrophages. We further demonstrated that OTUD1 directly binds to the CARD9 and then removes the K33-linked ubiquitin from CARD9 to promote the assembly of the CARD9-BCL10-MALT1 (CBM) complex, without affecting CARD9 stability. The ISO-activated CBM complex results in NF-κB activation and macrophage-based inflammatory gene overproduction, which then enhances cardiomyocyte hypertrophy and fibroblast fibrosis, respectively. Myeloid-specific OTUD1 deletion also attenuated ISO-induced murine cardiac inflammation and remodelling.
CONCLUSIONS: These results suggested that the OTUD1-CARD9 axis is a new pro-inflammatory signal in ISO-challenged macrophages and targeting this axis has a protective effect against ISO-induced HF.
KEY POINTS: Macrophage CARD9 was elevated in heart tissues of mice under chronic ISO administration. Either whole-body CARD9 knockout or myeloid-specific CARD9 deficiency protected mice from ISO-induced inflammatory heart remodeling. ISO promoted the assembly of CBM complex and then activated NF-κB signaling in macrophages through OTUD1-mediated deubiquitinating modification. OTUD1 deletion in myeloid cells protected hearts from ISO-induced injuries in mice.
Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 2 hours on days -6 and -5. Patients undergo TBI on days -1 and PBSCT on day 0.
Triple water/oil/water emulsions with a gelled aqueous external phase gelled with a crosslinked poly-(2-acrylamido-2-methylpropanesulphonic acid) and an oil phase which with an internal aqueous forms a primary water/oil emulsion. Triple water/oil/water emulsions comprise a gelled aqueous external phase, an oil phase which together with an internal aqueous phase forms a primary water/oil emulsion. The oil phase contains an emulsifying agent selected from alkyldimethicone copolyols and dimethicone copolyols and the external water phase contains: (1) at least one copolymeric emulsifying agent with a major proportion of monomer units of a 3-6 C monoethylenically unsaturated carboxylic acid or anhydride of this and a minor proportion of monomer units of a fatty ester of acrylic acid; and (2) at least one crosslinked poly(acrylamidomethylpropanesulphonic acid). The crosslinked poly(acrylamidomethylpropanesulphonic acid) contains, in random distribution: (a) 90-99.9 wt. % units of formula (III); and (b) 0.01-10 wt. % crosslinking units derived from at least one monomer having at least two olefinic double bonds. Independent claims are included covering: (a) a composition for topical application comprising an emulsion as claimed and at least one active agent; (b) use of the compositions for cleansing and/or treating and/or protecting the skin and/or the mucosa and/or keratinic fibres; and (c) a procedure for cleansing and/or treating and/or protecting the skin and/or keratinic fibres by applying to the skin, mucosa or keratinic fibres, a composition as claimed. X<+> = cation or cation mixture
Abstract A method of diagnosing and treating systemic Human Papilloma Virus (HPV) in particular "viral colonies" is disclosed. This method involves covering the skin of the feet and legs of a suspected infected human with topical applications selected from povidine iodine, potassium permanganate, aspirin, salicylic acid, natural salicin, lactic acid, alcohol, ether and any combination or mixture of them, and detecting "HPV colony centres" or lesions. The method of treatment of the detected HPV colony centres on the infected human includes topically administering any combination, mixture or percentage of aspirin, salicylic acid, natural salicin, paracetamol, phenacetin, whole natural grapefruit, povidine iodine and alcohol. These ingredients may be pureed, crushed, powered and or dissolved in water or grapefruit puree/juice, iodine or alcohol. The method optionally may contain the following further steps: a) initial intestinal cleansing with grapefruit seed extract(GSE) and /or Epsom salts, b) stretching and exercising the core infected area, c) i)treatment of the core infected area with firstly a topical treatment of any combination mixture or percentage of pureed whole potato and /or aloe vera stems mixed with either aspirin, salicylic acid, natural salicin, paracetamol, phenacetin, podivine iodine, alcohol, and/or epsom salts, then the core infected area is wrapped tightly in a sealed layer of plastic sheeting, and ii) secondly treating with another and final topical application consisting of any combinations, mixes and percentages of powdered Tobacco/nicotine, paracetamol, alcohol, Epsom salts, phenacetin, salicylic acid, salicin and/or aspirin. The method is supported or underpinned by a healthy lifestyle, a specified restrictive diet which avoids sugars and wheat products and certain vegetables and restricts the type and amounts of carbohydrates, a regime of daily specified supplements including salt, kelp, GSE, vitamin C, cod liver oil and Epsom salts and daily unprotected exposure to the sun.
Glioblastoma multiforme (GBM) remains incurable despite multimodal treatments after surgical debulking. Almost all patients with GBM relapse within a narrow margin (2-3 cm) of the initial resected lesion due to the unreachable residual cancerous cells. Here, a completely biodegradable microneedle for surgical cavity delivery glioblastoma-associated macrophages (GAMs)-activating immune nano-stimulator that mitigates glioblastoma relapse is reported. The residual tumor lesion-directed biocompatible microneedle releases the nano-stimulator and toll-like receptor 9 agonist in a controlled manner until the microneedles completely degrade over 1 week, efferently induce in situ phonotypic shifting of GAMs from anti- to pro-inflammatory and the tumor recurrence is obviously inhibited. The implantable microneedles offer a significant improvement over conventional transdermal ones, as they are 100% degradable, ensuring safe application within surgical cavities. It is also revealed that the T cells are recruited to the tumor niche as the GAMs initiate anti-tumor response and eradicate residual GBM cells. Taken together, this work provides a potential strategy for immunomodulating the postoperative tumor niche to mitigate tumor relapse in GBM patients, which may have broad applications in other malignancies with surgical intervention.
Neoadjuvant chemotherapy (NACT) is the standard of care for treatment of locally advanced breast cancer (LABC) and inflammatory breast cancer, and is recently being used in earlier stage breast cancer. The ideal outcome of NACT is pathological complete response (pCR), which itself has shown to be associated with improved disease-free survival. However, pCR is currently determined at the time of the surgery when the patient has received the whole cycle of the treatment. Early detection of non-responders to NACT could be used to halt ineffective treatment and start a new chemotherapeutic regimen in order to achieve better tumor response and overall survival. Current techniques to monitor response to NACT based on tumor size changes include mammography, physical examination, ultrasonography and MRI. Clinically assessing tumor size has been shown to be only moderately useful for chemotherapy response prediction in these patients because tumor shrinkage is a late marker of effective treatment. Metabolic activities and microstructure changes induced by NACT can be determined using functional imaging methods such as PET-CT, contrast enhanced MRI and diffuse optical spectroscopy. However, the application of these methods is limited due to high cost and intravenous injection of exogenous contrast agents. Limited studies have shown the potential of ultrasound elastography to be useful in predicting and monitoring response to NACT in breast cancer tumors based on tumor stiffness. Harmonic Motion Imaging (HMI) is a novel ultrasound elastography technique that applies an oscillatory force locally and at different depths in the tissue, in order to determine the characteristics of the resulting localized harmonic motion using high precision tracking methods. Highly localized harmonic motion can be noninvasively generated by ultrasonic beams deep inside the tissue and estimated at high precision, by using RF signals and cross-correlation methods. In addition to not being burdened by the drawbacks encountered by existing techniques, due to the highly localized and harmonic nature of the response, the motion characteristics can be directly linked to the local tissue stiffness. In this study, the investigators propose to compare the changes in the measurements provided by HMI and pathological response rate, between baseline, during treatment and end of the treatment to assess whether HMI can early predict the tumor response to neoadjuvant therapy.